Medicare Enrolled
Dr. Padma Draksharam, MD
Medical Oncology · Abilene, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Draksharam from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Draksharam? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Draksharam
Dr. Padma Draksharam is a medical oncology in Abilene, TX, with 13 years in practice. Based on federal Medicare data, Dr. Draksharam performed 71,280 Medicare services across 3,839 unique beneficiaries.
Between the years covered by Open Payments, Dr. Draksharam received a total of $4,367 from 40 pharmaceutical and/or device companies across 150 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Draksharam is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 13 years in practice▲ Top 14% volume in TX$ $4,367 industry payments
Medicare Practice Summary
Medicare Utilization ↗71,280
Medicare services
Top 14% in TX for medical oncology
3,839
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,483 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 39,270 | $0 | $5 |
| Contrast dye for imaging (iodine-based) | 6,601 | $0 | $3 |
| Iron sucrose injection (Venofer) | 5,800 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 5,300 | $43 | $137 |
| Darbepoetin injection (Aranesp) for anemia | 4,116 | $2 | $20 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,530 | $22 | $181 |
| Dexamethasone injection (steroid) | 942 | $0 | $1 |
| Blood draw (venipuncture) | 859 | $8 | $20 |
| Complete blood count (CBC) with differential | 707 | $8 | $36 |
| Comprehensive metabolic blood panel | 621 | $10 | $64 |
| Injection, granisetron hydrochloride, 100 mcg | 450 | $0 | $24 |
| Office visit, established patient (30-39 min) | 412 | $94 | $368 |
| Iron level test | 319 | $6 | $27 |
| Iron binding capacity test | 319 | $9 | $35 |
| Ferritin level test (iron stores) | 318 | $13 | $60 |
| Lactate dehydrogenase (enzyme) level | 232 | $6 | $31 |
| Office visit, established patient, complex (40-54 min) | 220 | $136 | $496 |
| Administration of chemotherapy into vein, 1 hour or less | 181 | $98 | $707 |
| Red blood count automated, with additional calculations | 176 | $5 | $26 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 171 | $22 | $157 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 139 | $48 | $313 |
| Microscopic examination for white blood cells with manual cell count | 126 | $4 | $22 |
| Complete blood count (CBC), automated | 126 | $6 | $34 |
| Office visit, established patient (20-29 min) | 122 | $65 | $250 |
| Administration of chemotherapy into vein, each additional hour | 80 | $22 | $161 |
| Injection, zoledronic acid, 1 mg | 80 | $7 | $431 |
| Reticulated (young) platelet measurement | 75 | $35 | $143 |
| Injection of additional new drug or substance into vein | 74 | $12 | $108 |
| Drug injection, under skin or into muscle | 71 | $11 | $96 |
| Injection, diphenhydramine hcl, up to 50 mg | 71 | $1 | $7 |
| Blood creatinine level | 69 | $5 | $31 |
| Urea nitrogen level to assess kidney function, quantitative | 69 | $4 | $24 |
| Blood potassium level | 64 | $5 | $30 |
| Albumin (protein) level | 63 | $5 | $28 |
| Bilirubin level, total | 63 | $5 | $23 |
| Calcium level, total | 63 | $5 | $30 |
| Carbon dioxide (bicarbonate) level | 63 | $5 | $24 |
| Blood chloride level | 63 | $5 | $25 |
| Phosphatase (enzyme) level, alkaline | 63 | $5 | $27 |
| Total protein level, blood | 63 | $4 | $42 |
| Liver enzyme (sgot), level | 63 | $5 | $33 |
| Liver enzyme (sgpt), level | 63 | $5 | $28 |
| Hospital follow-up visit, moderate complexity | 56 | $62 | $247 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 56 | $130 | $3,675 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 53 | $70 | $70 |
| Ct scan of chest with contrast | 52 | $53 | $821 |
| Carcinoembryonic antigen (cea) protein level | 52 | $19 | $99 |
| Uric acid level test | 51 | $4 | $25 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 51 | $26 | $145 |
| Administration of additional new drug or substance into vein, 1 hour or less | 51 | $49 | $344 |
| Irrigation of implanted venous access drug delivery device | 51 | $19 | $114 |
| Hospital follow-up visit, high complexity | 50 | $93 | $357 |
| CT scan of abdomen and pelvis with contrast | 49 | $167 | $1,067 |
| Infusion, normal saline solution , 1000 cc | 49 | $2 | $19 |
| New patient office visit, complex (60-74 min) | 47 | $155 | $709 |
| New patient office visit (45-59 min) | 42 | $115 | $565 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 41 | $20 | $128 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 41 | $337 | $1,722 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 37 | $16 | $100 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 30 | $1,127 | $4,802 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 30 | $87 | $657 |
| Infusion into a vein for hydration, each additional hour | 26 | $10 | $75 |
| Unclassified drugs | 24 | $1 | $8 |
| PSA test (prostate cancer screening) | 19 | $18 | $94 |
| Infusion into a vein for hydration, 31-60 minutes | 19 | $25 | $256 |
| Drawing of blood for a medical problem | 14 | $74 | $264 |
| Hospital discharge management, 30+ min | 12 | $89 | $368 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
55.7% high complexity
35.8% medium
8.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,367
Total received (2018-2024)
Avg $624/year across 7 years
Top 49% in TX for medical oncology
40
Companies
150
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,741 (85.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$626 (14.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$832
2023$1,106
2022$339
2021$70
2020$227
2019$949
2018$845
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$557
E.R. Squibb & Sons, L.L.C.
$504
PFIZER INC.
$461
GlaxoSmithKline, LLC.
$249
AstraZeneca Pharmaceuticals LP
$234
Merck Sharp & Dohme Corporation
$161
Lilly USA, LLC
$159
Gilead Sciences, Inc.
$139
Stemline Therapeutics Inc.
$120
ImmunoGen, Inc.
$117
Eisai Inc.
$115
Mirati Therapeutics, Inc.
$111
CTI BioPharma Corp.
$108
Novartis Pharmaceuticals Corporation
$106
Seagen Inc.
$102
PharmaEssentia USA Corporation
$97
SERVIER PHARMACEUTICALS LLC
$96
Genmab U.S., Inc.
$95
Merck Sharp & Dohme LLC
$86
Janssen Scientific Affairs, LLC
$82
TESARO, Inc.
$72
GENZYME CORPORATION
$70
EMD Serono, Inc.
$63
Teva Pharmaceuticals USA, Inc.
$57
Clovis Oncology, Inc.
$48
Boehringer Ingelheim Pharmaceuticals, Inc.
$42
Ipsen Biopharmaceuticals, Inc
$34
AMAG Pharmaceuticals, Inc.
$31
Octapharma USA, Inc.
$31
Daiichi Sankyo Inc.
$28
Bayer HealthCare Pharmaceuticals Inc.
$27
Incyte Corporation
$24
Rigel Pharmaceuticals, Inc.
$24
Janssen Biotech, Inc.
$23
Karyopharm Therapeutics Inc.
$21
Astellas Pharma US Inc
$17
EISAI INC.
$15
Celgene Corporation
$14
Exelixis Inc.
$14
Takeda Pharmaceuticals U.S.A., Inc.
$12
Top 3 companies account for 34.9% of total payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · ALUNBRIG · BENDEKA · BESREMI · BOSULIF · Bavencio · CYRAMZA · Cabometyx · DARZALEX · ERLEADA · Elahere · Epkinly · FERAHEME · GILOTRIF · Halaven · IBRANCE · IMFINZI · INJECTAFER · JADENU · JAKAFI · JAYPIRCA · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LUMAKRAS · LYNPARZA · Lenvima · Neulasta · Nexavar · Nplate · OJJAARA · OPDIVO · Orserdu · PADCEV · PROMACTA · Pomalyst · REBLOZYL · RYDAPT · Rubraca · SOMATULINE DEPOT · SUTENT · Stivarga · TAGRISSO · TALZENNA · TAXOTERE · Tavalisse · Tibsovo · Trodelvy · Vectibix · Vonjo · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XPOVIO · XTANDI · ZEJULA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (86%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $6 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
4
Per 100K population
2.8
County median income
$66,406
Nearest hospital
OCEANS BEHAVIORAL HOSPITAL OF ABILENE
8.9 mi
8.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Draksharam is a mixed practice specialist, with above-average Medicare volume (top 14% in TX), and low-engagement industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Draksharam experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Draksharam performed 39,270 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Draksharam receive payments from pharmaceutical companies?
Yes. Dr. Draksharam received a total of $4,367 from 40 companies across 150 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Draksharam's costs compare to other medical oncologys in Abilene?
Dr. Draksharam's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Draksharam) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Abilene
Browse medical oncologys in Abilene ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc..
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology